neuromyelitis optica spectrum disorder
Phase 3 results announced for Imfinzi plus Imdelltra in extensive-stage small cell lung cancer
Around 195,000 people globally will be treated for this form of lung cancer in 2026
Amgen agrees to lower prescription drug costs in deal with US government
The company has invested $40bn in US R&D and manufacturing in the past seven years
Amgen reports positive results from landmark cardiovascular study
The study found significant reductions of major cardiovascular events in high-risk adults following treatment
Amgen commits $650m to US manufacturing expansion
The investment is expected to generate up to 750 new jobs
Amgen and Kyowa Kirin announce rocatinlimab results for atopic dermatitis
The phase 3 study included around 2,600 patients
Amgen’s bemarituzumab shows promise in phase 3 gastric cancer study
Almost one million new cases of gastric cancer are diagnosed globally every year
Amgen’s Uplizna approved by FDA as first treatment for rare disease IgG4-RD
Immunoglobulin G4-related disease affects approximately 20,000 people in the US
Amgen’s Uplizna shows promise in phase 3 generalised myasthenia gravis study
Regulatory submissions are expected to be complete in the first half of this year
Amgen/Kyowa Kirin share promising phase 3 results for rocatinlimab in atopic dermatitis
The inflammatory skin disease affects up to 20% of children and 10% of adults worldwide
Amgen’s Blincyto recommended by NICE for new adult leukaemia indication
Up to 50% of acute lymphoblastic leukaemia patients will relapse after initial treatment
Amgen’s Blincyto granted EC approval for new acute lymphoblastic leukaemia indication
B-ALL is the most common form of the blood cancer, accounting for approximately 75% of adult cases
Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer
The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations